Yang Sun

Dr. Yang Sun


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YSYang Sun
Yang Sun
LHLu Hu
Lu Hu
Zhipeng (Toby) TaoZhipeng (Toby) Tao
Zhipeng (Toby) Tao
GJGopala K. Jarugumilli
Gopala K. Jarugumilli
HEHannah Erb
Hannah Erb
XWXu Wu
Xu Wu
Targeting TEAD autopalmitoylation has been proposed as a therapeutic approach for YAP-dependent cancers. Here we show that TEAD palmitoylation inhibitor MGH-CP1 and analogues block cancer cell “stemness”, organ overgrowth and tumor initiation in vitro and in vivo. MGH-CP1 sensitivity correlates significantly with YAP-dependency in a large panel of cancer cell lines. However, TEAD inhibition or YAP/TAZ knockdown leads to transient inhibition of cell cycle progression without inducing cell death, undermining their potential therapeutic utilities. We further reveal that TEAD inhibition or YAP/TAZ silencing leads to VGLL3-mediated transcriptional activation of SOX4/PI3K/AKT signaling axis, which contributes to cancer cell survival and confers therapeutic resistance to TEAD inhibitors. Consistently, combination of TEAD and AKT inhibitors exhibits strong synergy in inducing cancer cell death. Our work characterizes the therapeutic opportunities and limitations of TEAD palmitoylation inhibitors in cancers, and uncovers an intrinsic molecular mechanism, which confers potential therapeutic resistance.

19 September 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
LSLiang Sun
Liang Sun
HMHanjing Meng
Hanjing Meng
TLTao Liu
Tao Liu
QZQiong Zhao
Qiong Zhao
MXMingyi Xia
Mingyi Xia
YLYong Liu
Yong Liu
Cancer cells undergo metabolic reprogramming that is intricately linked to malignancy. Protein acylations are especially responsive to metabolic changes, influencing signal transduction pathways and fostering cell proliferation. However, as a novel type of acylations, the involvement of malonylation in cancer remains poorly understood. In this study, we observed a significant reduction in malonyl-CoA levels in hepatocellular carcinoma (HCC), which correlated with a global decrease in malonylation. Subsequent nuclear malonylome analysis unveiled nucleolin (NCL) malonylation, which was notably enhanced in HCC biopsies. we demonstrated that NCL undergoes malonylation at lysine residues 124 and 398. This modification triggers the translocation of NCL from the nucleolus to nucleoplasm and cytoplasm, binding to AKT mRNA, and promoting AKT translation in HCC. Silencing AKT expression markedly attenuated HCC cell proliferation driven by NCL malonylation. These findings collectively highlight nuclear signaling in modulating AKT expression, suggesting NCL malonylation as a novel mechanism through which cancer cells drive cell proliferation.

12 September 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
JYJiatian Yu
Jiatian Yu
PLPan Li
Pan Li
YYYing Yu
Ying Yu
YMYan Ma
Yan Ma
SZShurun Zuo
Shurun Zuo
YSYang Sun
Yang Sun
The human body harbors a diverse microbiota across various anatomical sites, including the lungs, which play a crucial role in maintaining respiratory health and influencing disease outcomes. This review synthesizes current research on the lung microbiota's impact on pulmonary diseases, emphasizing its interactions with microbiota from other body regions, such as the gut and oral cavity. Emerging evidence suggests that lung microbiota dysbiosis is intricately linked to the pathogenesis of various pulmonary diseases, including idiopathic pulmonary fibrosis, lung cancer, pneumonia, asthma, and chronic obstructive pulmonary disease (COPD). The review highlights the significance of understanding these microbial interactions to advance diagnostic, preventive, and therapeutic strategies for respiratory diseases. By elucidating the mechanisms through which microbiota influence lung health, this review underscores the potential of microbiome-based diagnostics and therapeutics in revolutionizing the management of pulmonary diseases, paving the way for personalized medicine and innovative treatment approaches.

3 September 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
YTYang Tian
Yang Tian
WLWei Li
Wei Li
QZQing Zhai
Qing Zhai
YYYing Yu
Ying Yu
JYJiaxin Yuan
Jiaxin Yuan
YSYang Sun
Yang Sun
Protein S‐palmitoylation, a dynamic and reversible post‐translational modification involving the attachment of palmitate to cysteine residues, is a key regulator of protein functionality and cellular signalling. Dysregulation of this modification has emerged as a critical driver of cancer progression. Among the 23 DHHC palmitoyl transferases responsible for catalysing S‐palmitoylation, aberrant expression of specific members is linked to tumorigenesis and development, underscoring their potential as promising therapeutic targets. However, the cancer‐specific roles and substrates of individual DHHC enzymes remain poorly characterised. In this study, we identified DHHC9 as a crucial regulator of adenocarcinoma progression, including colorectal and lung cancers. Functional studies demonstrated that DHHC9 knockdown profoundly inhibited cell migration in vitro and tumour metastasis in vivo. Proteomic and functional analyses revealed that STRN4, a core component of the STRIPAK complex, was palmitoylated by DHHC9 at cysteine 701. The STRN4 palmitoylation reduced YAP phosphorylation, promoted nuclear translocation of YAP and activated downstream Hippo pathway transcriptional targets—including CCN1, CCN2 and ANKRD1—thereby driving cancer cell migration. Notably, we discovered two small molecules, Treprostinil and 10‐HCPT, as potent DHHC9 inhibitors that effectively suppressed adenocarcinoma cell migration. Our findings define the DHHC9‐STRN4‐YAP axis as a novel mechanism linking palmitoylation to phosphatase regulation and Hippo pathway dysregulation, unveiling DHHC9 as a highly promising therapeutic target in cancer treatment.

11 September 2026 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
WCWenwen Chang
Wenwen Chang
JYJiaxin Yuan
Jiaxin Yuan
HZHuilin Zhang
Huilin Zhang
YYYing Yu
Ying Yu
YMYan Ma
Yan Ma
YSYang Sun
Yang Sun
Drug‑tolerant persister cells represent a major barrier to durable responses in cases of epidermal growth factor receptor (EGFR)‑mutant lung adenocarcinoma treated with tyrosine kinase inhibitors. To define the molecular features and actionable vulnerabilities of this cell state, public transcriptomic datasets from tumour cell‑based models treated with EGFR inhibitors or other targeted agents within the receptor tyrosine kinase (RTK)/RAS/MAPK pathway were integrated with machine‑learning‑based feature selection, survival analysis and Cancer Dependency Map‑based pharmacogenomic screening. The present study also performed experimental validation of identified genes and drugs in PC‑9 and HCC827 cell models. A four‑gene persister‑associated gene signature comprising B‑cell translocation gene 1 protein, inhibitor of growth protein 4, proline‑rich nuclear receptor coactivator 1 and calcium‑binding and coiled‑coil domain‑containing protein 1 was identified, which defined a targeted therapy‑induced persister state and associated with poor patient survival. Functional validation using reverse transcription‑quantitative PCR, doxycycline‑inducible short hairpin RNA knockdown and β‑galactosidase staining assays demonstrated rapid induction of these genes during osimertinib treatment and showed that depletion of each gene markedly impaired drug‑tolerant persister cell formation. Pharmacogenomic analysis identified ZLN005, a peroxisome proliferator‑activated receptor γ coactivator‑1α agonist, as a candidate metabolic modulator that synergized with osimertinib to reduce persister cell viability. Mechanistically, ZLN005 enhanced mitochondrial oxidative metabolism and reactive oxygen species accumulation, leading to caspase‑3 activation and gasdermin E‑associated pyroptotic cell death. Collectively, these findings defined the transcriptional and metabolic features of targeted therapy‑induced persister cells and revealed a metabolic vulnerability to ZLN005 in EGFR‑mutant lung adenocarcinoma.